MediciNova, Inc.
Financial Summary 2026 Fiscal Year 2Q (Interim)
Highlights for the second quarter of the 2026 fiscal year. Operating revenue was 103,732 thousand yen, net income for the period was -787,591 thousand yen. R&D costs were 368,318 thousand yen, SG&A expenses were 549,655 thousand yen. The latest quarter's revenue is included as a component, and YoY comparison and segment information are included in the financial statements summary.
Key Figures
- Operating Revenue: 103,732千円
- Operating Income: -864,190千円
- Net Income: -787,591千円
AI要約
Summary of Results
In this interim period, revenue is recorded at 103,732 thousand yen while operating income is -864,190 thousand yen and net income is -787,591 thousand yen. The largest cost items are SG&A (549,655 thousand yen) and R&D/Patent costs (368,318 thousand yen), with continued R&D investment. Although currently in a loss, continued R&D investment is emphasized, and progress in clinical trials and pipeline advancement is expected to help improve future cash flows.
Outlook and Initiatives
The financial highlights also note the progress of major clinical programs, with ongoing development of MN-166, MN-001, etc. The timing of topline data disclosure and data analysis completion is limited to certain sections, and future approval prospects depend on these data analysis results. On the financial side, investors are likely to focus on cash and cash equivalents movements, funding options, and progress of cost-containment measures.
MediciNova, Inc.（メディシノバ・インク）
Company overview · Stock price · Financial data · All IR
